EML4/ALK and Ras Inhibitors

被引：0
|
作者：
Edelman, Martin J. [1 ]
机构：
[1] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 12期
关键词：
CELL LUNG-CANCER; EML4-ALK; IDENTIFICATION;
D O I：
10.1097/01.JTO.0000391381.40050.5c
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S495 / S496
页数：2
相关论文
共 50 条
  • [41] Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors
    Zhang, Guolin
    Scarborough, Hannah
    Kim, Jihye
    Rozhok, Andrii I.
    Chen, Yian Ann
    Zhang, Xiaohui
    Song, Lanxi
    Bai, Yun
    Fang, Bin
    Liu, Richard Z.
    Koomen, John
    Tan, Aik Choon
    Degregori, James
    Haura, Eric B.
    SCIENCE SIGNALING, 2016, 9 (450)
  • [42] An experimental model for in vivo treatment with ALK inhibitors of EML4-ALK-positive lung cancer
    Soda, Manabu
    Takada, Shuji
    Takeuchi, Kengo
    Hatanaka, Hisashi
    Yamashita, Yoshihiro
    Ishikawa, Yuichi
    Sugiyama, Yukihiko
    Mano, Hiroyuki
    CANCER RESEARCH, 2009, 69
  • [43] EML4-ALK AND ITS INHIBITORS: A NEW PARADIGM IN CANCER TREATMENT
    Mano, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 79 - 79
  • [44] EML4 promotes the loading of NUDC to the spindle for mitotic progression
    Chen, Dan
    Ito, Satoko
    Yuan, Hong
    Hyodo, Toshinori
    Kadomatsu, Kenji
    Hamaguchi, Michinari
    Senga, Takeshi
    CELL CYCLE, 2015, 14 (10) : 1529 - 1539
  • [45] Transcriptomic overview of EML4-ALK lung cancer cells resistant to ALK inhibitors highlights a vulnerability to CDK inhibitors
    Paliouras, Athanasios R.
    Magee, Peter
    Sahoo, Sudhakar
    Leong, Hui Sun
    Krebs, Matthew
    Blackhall, Fiona
    Lovly, Christine M.
    Garofalo, Michela
    CANCER RESEARCH, 2019, 79 (13)
  • [46] Evaluating the frequencies of EGFR, ALK/EML4, and ROS1 alterations in lung cancer: A single-center experience
    Aras, B. Durak
    Cilingir, O.
    Isik, S.
    Arslan, S.
    Dundar, E.
    Ak, G.
    Temena, M. A.
    Erzurumluoglu, E.
    Gunden, G.
    Artan, S.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1563 - 1564
  • [47] Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations
    Bearz, Alessandra
    Martini, Jean-Francois
    Jassem, Jacek
    Kim, Sang-We
    Chang, Gee-Chen
    Shaw, Alice T.
    Shepard, Deborah A.
    Dall'O, Elisa
    Polli, Anna
    Thurm, Holger
    Zalcman, Gerard
    Campelo, Maria Rosario Garcia
    Penkov, Konstantin
    Hayashi, Hidetoshi
    Solomon, Benjamin J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : 1581 - 1593
  • [48] Different response to ALK inhibitors in EML4-ALK positive mediastinal cancer of unknown primary.
    Hu, Chunhong
    Zhao, Lishu
    Wu, Fang
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models
    E Normant
    G Paez
    K A West
    A R Lim
    K L Slocum
    C Tunkey
    J McDougall
    A A Wylie
    K Robison
    K Caliri
    V J Palombella
    C C Fritz
    Oncogene, 2011, 30 : 2581 - 2586
  • [50] Echinoderm Microtubule-Associated Protein-Like 4 (EML4)-Anaplastic Lymphoma Kinase (ALK) Rearrangement in Congenital Pulmonary Airway Malformation
    Tetsumoto, Satoshi
    Kijima, Takashi
    Morii, Eiichi
    Goya, Sho
    Minami, Toshiyuki
    Hirata, Haruhiko
    Takahashi, Ryo
    Kohmo, Satoshi
    Inoue, Koji
    Nagatomo, Izumi
    Takeda, Yoshito
    Kida, Hiroshi
    Tachibana, Isao
    Kumanogoh, Atsushi
    CLINICAL LUNG CANCER, 2013, 14 (04) : 457 - 460
12345